Eli Lilly | Des Atouts



Assets Changement Date
AbbVie USD 136.17B 1B 2025-03
Abbott USD 84B 2.55B 2025-06
ALKERMES USD 2.25B 170.83M 2025-06
Amgen USD 87.9B 1.47B 2025-06
AstraZeneca USD 112.42B 6.17B 2025-06
Baxter International USD 21.3B 4.48B 2025-03
Biogen USD 28.33B 297.1M 2025-06
Bristol-Myers Squibb USD 94.68B 2.25B 2025-06
Drreddys Laboratories INR 481.06B 15.1B 2024-12
Eli Lilly USD 100.92B 11.53B 2025-06
Gilead Sciences USD 55.72B 713M 2025-06
GlaxoSmithKline GBP 59.26B 1.45B 2025-06
Glaxosmithkline GBP 59.46B 1.41B 2024-12
J&J USD 193.67B 13.57B 2025-03
Medtronic USD 91.68B 1.71B 2025-04
Merck USD 115.12B 1.98B 2025-03
Neurocrine Biosciences USD 3.89B 202.1M 2025-06
Novartis USD 104.4B 4.45B 2025-06
Novartis USD 102.25B 1.28B 2024-12
Novo Nordisk 482.15B 7.01B 2025-06
Perrigo USD 10.09B 334.3M 2025-06
Pfizer USD 206.1B 1.93B 2025-06
Prestige Brands USD 3.43B 29.41M 2025-06
Regeneron Pharmaceuticals USD 38.22B 674M 2025-06
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 124.96B 6.93B 2025-06
Sanofi 132.8B 3.04B 2024-12
United Therapeutics USD 7.91B 164.1M 2025-06
Zoetis USD 14.48B 381M 2025-06


Eli Lilly Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.